Literature DB >> 146331

[Combination chemotherapy in patients with disseminated bronchogenic carcinoma (author's transl)].

C Gropp, K Havemann, W D Gassel, F Hess, R Prignitz, M Schmidt, C P Sodomann.   

Abstract

49 patients with disseminated bronchogenic carcinoma (small cell, 16;squamous cell, 17;large cell, 12;adeno, 4) were treated with a combination of adriamycin, cyclophosphamide, vincristine and DTIC. In a randomized series (21 patients) chemotherapy alone was compared to chemotherapy plus heparin. Partial remission was achieved in 8 patients with small cell carcinoma, in 5 patients with large carcinoma and in 2 patients with squamous cell carcinoma. The survival of patients who responded to therapy was greater than the survival of patients who did not respond to therapy. The duration of remission and the survival time was not longer in patients who had additional heparin therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 146331     DOI: 10.1007/bf00284303

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  14 in total

1.  Combination chemotherapy in oat cell carcinoma of the lung.

Authors:  D W Nixon; R W Carey; H D Suit; A C Aisenberg
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

2.  Combination chemotherapy of advanced lung cancer: a randomized trial.

Authors:  H H Hansen; O S Selawry; R Simon; D T Carr; C E van Wyk; R D Tucker; R Sealy
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

3.  Intensive combined chemotherapy and radiotherapy in patients with nonresectable bronchogenic carcinoma.

Authors:  H H Hansen; F M Muggia; R Andrews; O S Selawry
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

4.  Aspects of the immunologic treatment of lung cancer.

Authors:  G Alth; H Denck; M Fischer; K Karrer; O Kokron; E Korizek; M Micksche; E Ogris; C Reider; R Titscher; H Wrba
Journal:  Cancer Chemother Rep 3       Date:  1973-03

5.  A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases.

Authors:  J M Brown
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

6.  Alkylating agents in bronchogenic carcinoma.

Authors:  R A Green; E Humphrey; H Close; M E Patno
Journal:  Am J Med       Date:  1969-04       Impact factor: 4.965

7.  Therapy of advanced squamous carcinoma of the lung: cyclophosphamide vesus "COMB".

Authors:  G P Bodey; S W Lagakos; A C Gutierrez; H E Wilson; O S Selawry
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

8.  BACON (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patients.

Authors:  R B Livingston; W H Fee; L H Einhorn; M A Burgess; E J Freireich; J A Gottlieb; M O Farber
Journal:  Cancer       Date:  1976-03       Impact factor: 6.860

9.  Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat.

Authors:  D Agostino; E E Cliffton; A Girolami
Journal:  Cancer       Date:  1966-02       Impact factor: 6.860

10.  Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy, including methotrexate, cyclophosphamide, procarbazine and vincristine.

Authors:  P Alberto; K W Brunner; G Martz; J Obrecht; R W Sonntag
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

View more
  1 in total

1.  Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems.

Authors:  B Maat; P Hilgard
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.